These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 9626635

  • 1. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
    Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ.
    J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
    [Abstract] [Full Text] [Related]

  • 2. Paget's disease of bone: reduction of disease activity with oral risedronate.
    Hosking DJ, Eusebio RA, Chines AA.
    Bone; 1998 Jan; 22(1):51-5. PubMed ID: 9437513
    [Abstract] [Full Text] [Related]

  • 3. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V.
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [Abstract] [Full Text] [Related]

  • 4. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
    Brown JP, Hosking DJ, Ste-Marie L, Johnston CC, Reginster J, Ryan WG, Johnson TD, Bekker PJ.
    Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
    [Abstract] [Full Text] [Related]

  • 5. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 6. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 01; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 7. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
    Singer FR, Clemens TL, Eusebio RA, Bekker PJ.
    J Clin Endocrinol Metab; 1998 Jun 01; 83(6):1906-10. PubMed ID: 9626117
    [Abstract] [Full Text] [Related]

  • 8. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul 01; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 9. Risedronate: clinical usage.
    Chapurlat RD, Delmas PD.
    Int J Clin Pract; 2001 May 01; 55(4):275-8. PubMed ID: 11406915
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ.
    Am J Med; 1999 May 01; 106(5):513-20. PubMed ID: 10335722
    [Abstract] [Full Text] [Related]

  • 11. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM.
    J Bone Miner Res; 1995 Mar 01; 10(3):458-65. PubMed ID: 7785468
    [Abstract] [Full Text] [Related]

  • 12. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr 01; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 13. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA.
    Arthritis Rheum; 1999 Nov 01; 42(11):2309-18. PubMed ID: 10555025
    [Abstract] [Full Text] [Related]

  • 14. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
    Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW.
    Bone; 2000 Mar 01; 26(3):263-7. PubMed ID: 10709999
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.
    J Bone Miner Res; 2005 Dec 01; 20(12):2105-15. PubMed ID: 16294264
    [Abstract] [Full Text] [Related]

  • 16. Risedronate: a new oral bisphosphonate.
    Umland EM, Boyce EG.
    Clin Ther; 2001 Sep 01; 23(9):1409-21. PubMed ID: 11589256
    [Abstract] [Full Text] [Related]

  • 17. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
    Dunn CJ, Goa KL.
    Drugs; 2001 Sep 01; 61(5):685-712. PubMed ID: 11368289
    [Abstract] [Full Text] [Related]

  • 18. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar 01; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 19. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A, Bouzid K, Sahli H, Sallami S, Abdelmoula J.
    Tunis Med; 2009 Jun 01; 87(6):380-1. PubMed ID: 19927782
    [Abstract] [Full Text] [Related]

  • 20. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG, Sod E, Johnson T, Chines A.
    Calcif Tissue Int; 2004 Dec 01; 75(6):469-76. PubMed ID: 15478000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.